Literature DB >> 15082832

Longitudinal transcriptional analysis of developing neointimal vascular occlusion and pulmonary hypertension in rats.

Laszlo T Vaszar1, Toshihiko Nishimura, John D Storey, Guohua Zhao, Daoming Qiu, John L Faul, Ronald G Pearl, Peter N Kao.   

Abstract

Pneumonectomized rats injected with the alkaloid toxin, monocrotaline, develop progressive neointimal pulmonary vascular obliteration and pulmonary hypertension resulting in right ventricular failure and death. The antiproliferative immunosuppressant, triptolide, attenuates neointimal formation and pulmonary hypertension in this disease model (Faul JL, Nishimura T, Berry GJ, Benson GV, Pearl RG, and Kao PN. Am J Respir Crit Care Med 162: 2252-2258, 2000). Pneumonectomized rats, injected with monocrotaline on day 7, were killed at days 14, 21, 28, and 35 for measurements of physiology and gene expression patterns. These data were compared with pneumonectomized, monocrotaline-injected animals that received triptolide from day 5 to day 35. The hypothesis was tested that a group of functionally related genes would be significantly coexpressed during the development of disease and downregulated in response to treatment. Transcriptional analysis using total lung RNA was performed on replicate animals for each experimental time point with exploratory data analysis followed by statistical significance analysis. Marked, statistically significant increases in proteases (particularly derived from mast cells) were noted that parallel the development of vascular obliteration and pulmonary hypertension. Mast-cell-derived proteases may play a role in regulating the development of neointimal pulmonary vascular occlusion and pulmonary hypertension in response to injury.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15082832     DOI: 10.1152/physiolgenomics.00198.2003

Source DB:  PubMed          Journal:  Physiol Genomics        ISSN: 1094-8341            Impact factor:   3.107


  7 in total

1.  Idiopathic pulmonary arterial hypertension: an avian model for plexogenic arteriopathy and serotonergic vasoconstriction.

Authors:  Robert F Wideman; Krishna R Hamal
Journal:  J Pharmacol Toxicol Methods       Date:  2011-01-26       Impact factor: 1.950

2.  A Review of Transcriptome Analysis in Pulmonary Vascular Diseases.

Authors:  Dustin R Fraidenburg; Roberto F Machado
Journal:  Methods Mol Biol       Date:  2018

3.  New dynamic viewing of mast cells in pulmonary arterial hypertension (PAH): contributors or outsiders to cardiovascular remodeling.

Authors:  Jian Xu; Jingjing Wang; Chengjie Shao; Xiaoning Zeng; Lixiang Sun; Hui Kong; Weiping Xie; Hong Wang
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

4.  Gene expression analysis of a murine model with pulmonary vascular remodeling compared to end-stage IPAH lungs.

Authors:  Kayoko Shimodaira; Yoichiro Okubo; Eri Ochiai; Haruo Nakayama; Harutaka Katano; Megumi Wakayama; Minoru Shinozaki; Takao Ishiwatari; Daisuke Sasai; Naobumi Tochigi; Tetsuo Nemoto; Tsutomu Saji; Katsuhiko Kamei; Kazutoshi Shibuya
Journal:  Respir Res       Date:  2012-11-17

Review 5.  Microarray analysis in pulmonary hypertension.

Authors:  Julia Hoffmann; Jochen Wilhelm; Andrea Olschewski; Grazyna Kwapiszewska
Journal:  Eur Respir J       Date:  2016-04-13       Impact factor: 16.671

Review 6.  Cathepsin S: investigating an old player in lung disease pathogenesis, comorbidities, and potential therapeutics.

Authors:  Ryan Brown; Sridesh Nath; Alnardo Lora; Ghassan Samaha; Ziyad Elgamal; Ryan Kaiser; Clifford Taggart; Sinéad Weldon; Patrick Geraghty
Journal:  Respir Res       Date:  2020-05-12

Review 7.  Application and Mechanisms of Triptolide in the Treatment of Inflammatory Diseases-A Review.

Authors:  Kai Yuan; Xiaohong Li; Qingyi Lu; Qingqing Zhu; Haixu Jiang; Ting Wang; Guangrui Huang; Anlong Xu
Journal:  Front Pharmacol       Date:  2019-12-06       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.